SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000891293-22-000008
Filing Date
2022-03-31
Accepted
2022-03-31 16:04:24
Documents
14
Period of Report
2022-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ctic-20220331.htm   iXBRL 8-K 36938
2 EX-99.1 ex991earningsreleaseq42021.htm EX-99.1 61652
6 cti_logoxrgbx1501a.jpg GRAPHIC 25747
  Complete submission text file 0000891293-22-000008.txt   275034

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ctic-20220331.xsd EX-101.SCH 1927
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ctic-20220331_lab.xml EX-101.LAB 24197
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ctic-20220331_pre.xml EX-101.PRE 12543
8 EXTRACTED XBRL INSTANCE DOCUMENT ctic-20220331_htm.xml XML 10565
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-28386 | Film No.: 22792370
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences